PRM — Big Pharma Split Income Statement
0.000.00%
Last trade - 00:00- CA$17.88m
- -CA$7.48m
- CA$0.66m
- 80
- 80
- 52
- 81
Annual income statement for Big Pharma Split, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.789 | 5.62 | 4.03 | 0.542 | 0.661 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 0.524 | 0.768 | 0.882 | 0.682 | 0.647 |
| Operating Profit | 0.265 | 4.85 | 3.15 | -0.14 | 0.013 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.217 | 4.21 | 2.39 | -0.645 | -0.539 |
| Net Income After Taxes | -0.217 | 4.21 | 2.39 | -0.645 | -0.539 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.217 | 4.21 | 2.39 | -0.645 | -0.539 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.217 | 4.21 | 2.39 | -0.645 | -0.539 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.218 | 3.27 | 1.58 | -0.53 | -0.469 |
| Dividends per Share | |||||
| Special Dividends per Share |